Dr Ros Jones, MBBS, MD, FRCPCH – C
Ros was a Consultant Paediatrician for 30 years, with a special interest in neonatal intensive care and paediatric HIV. She has served on the Advisory Committee of the National Perinatal Epidemiology Unit and on the Education & Training committee of the RCPCH. An active member for many years in the British Perinatal Trials Group, she was also involved in reviewing NICE guidelines alongside some editorial work. Since retiring from the NHS, she has undertaken several tours teaching on SAFE Obstetrics courses in countries in Africa.
Since covid, she has been a spokesperson for the Health Advisory & Recovery Team (HART) and has also led a group of health professionals and scientists in writing letters to the regulatory authorities about the balance of benefit and risks for covid-19 vaccines in childhood.
Professor Angus Dalgleish,
MD, FRCP, FRACP, FRCPath, FMed Sci
Professor Angus Dalgleish is Professor of Oncology, St Georges Hospital, London, Principal, Institute for Cancer Vaccines and Immunotherapy.
David Critchley, BSc., PhD
David’s PhD in pharmacology was sponsored by Pfizer. He has more than 30 years experience in drug discovery and development in roles covering preclinical pharmacology, drug metabolism & pharmacokinetics and clinical pharmacology. He has worked on antiviral projects for HIV for Roche and has anti-infective experience in antiparasitic, antifungal and antibiotic drug discovery. As Eisai’s Global Head of Clinical Pharmacology he supported many new drug approvals including diethylcarbamazine (WHO), rufinamide, perampanel, zonisamide, lenvatinib and eribulin, as well as approvals for cannabidiol for the treatment of childhood epilepsy syndromes at GW.
Dr John Flack, BPharm, PhD.
John has 40 years experience in senior R&D and executive positions in pharmaceuticals and biotechnology. He attained a PhD in the Dept. of Pharmacology, School of Pharmacy, London University and a post-doctoral fellowship at the Worcester Foundation for Experimental Biology in Massachusetts, U.S.A.
He was Director of Safety Evaluation at Beecham Pharmaceuticals and Senior Vice-president for Drug Discovery at SmithKline Beecham, during which time nabumetone (an anti-inflammatory), paroxetine (an anti-depressant), granisetron (an anti-emetic), Eminase (a thrombolytic), Augmentin (an oral anti-bacterial), Timentin (an injectable anti-bacterial), penciclovir/famciclovir (injectable/oral antivirals), Bactroban (a topical anti-bacterial) were discovered, developed and registered for marketing.
More recently, John has volunteered at his local vaccination centre helping the NHS roll out COVID-19 vaccines in the community.
Professor David Livermore
David Livermore began his career in 1980 as Research Assistant at the London Hospital Medical College, writing a PhD ‘On the side’. By 1994 he’d risen to Senior Lecturer in Medical Microbiology. In 1997 he moved to the Public Health Laboratory Service, now Public Health England, swiftly becoming Director of its Antimicrobial Resistance Monitoring and Reference Laboratory. He remained until 2011, when he transferred to the University of East Anglia as Professor of Medical Microbiology.
Across 40 years he has belonged and led teams that have defined the evolving epidemiology and molecular nature of antimicrobial resistance. He has authored over 500 papers and has served on UK government advisory committees on antimicrobial resistance and healthcare-infection.
